All In Biotech

Drug Trial Radar · NCT00175903

Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy

A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.

Last checked: Nov 19, 2026Latest source record: Mar 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,701 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,701

Actual

Start

Feb 2005

Primary completion

Oct 2007

Study completion Oct 2007

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.

Conditions

  • Epilepsy

Interventions

  • LevetiracetamDrug

    Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.

  • Carbamazepine Controlled Release (CBZ-CR)Drug

    Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.

  • Valproate Extended ReleaseDrug

    Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to withdrawal from study medication (starting at V1) as a measure of combined efficacy and safetyTime frame: Visit 1 to End of Study (approximately 52 weeks)

Locations

229 sites in 24 countries. Site status is shown where the registry gives one.

  • Site not named

    Adelaide, Australia

  • Site not named

    Bedford Park, Australia

  • Site not named

    Brisbane, Australia

  • Site not named

    Cairns, Australia

  • Site not named

    Camperdown, Australia

  • Site not named

    Chatswood, Australia

  • Site not named

    Clayton, Australia

  • Site not named

    Maroochydore, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Perth, Australia

  • Site not named

    Randwick, Australia

  • Site not named

    West Heidelberg, Australia

  • Site not named

    Graz, Austria

  • Site not named

    Innsbrick, Austria

  • Site not named

    Klagenfurt, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Steyr, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Bruges, Belgium

  • Site not named

    Dendermonde, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Haine-Saint-Paul, Belgium

  • Site not named

    Jette, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Ostend, Belgium

  • Site not named

    Ottignies, Belgium

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Litomyšl, Czechia

  • Site not named

    Ostrava-Poruba, Czechia

  • Site not named

    Zlín, Czechia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Holbæk, Denmark

  • Site not named

    Holstebro, Denmark

  • Site not named

    Hus (Helsinki), Finland

  • Site not named

    Kuopio, Finland

Showing 40 of 229 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.